SynAct Pharma AB (STO:SYNACT)

SynAct Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-82.4	-215.81	-99.21	-69.3	-26.55
Depreciation & Amortization	-	75.34	1.02	0.09	-
Loss (Gain) From Sale of Assets	-	-0.04	-0.01	-	-
Stock-Based Compensation	-	7.88	-	-	-
Other Operating Activities	11.48	2.09	1	-2.88	-3.92
Change in Accounts Receivable	-	19.87	-19.31	-1.21	-0.53
Change in Accounts Payable	-	5.11	0.18	1.44	-0.33
Change in Other Net Operating Assets	-18.28	5.39	-1.22	6.87	-1.91
Operating Cash Flow	-89.2	-100.18	-117.56	-65	-33.24
Investment in Securities	-	0.37	0.03	-0.01	-0.09
Investing Cash Flow	-	0.37	0.03	-0.01	-0.09
Long-Term Debt Repaid	-	-0.73	-0.98	-0.08	-
Net Debt Issued (Repaid)	-	-0.73	-0.98	-0.08	-
Issuance of Common Stock	-	59.46	228.95	80	49.76
Other Financing Activities	87.41	-4.75	-27.25	-5.6	-5.04
Financing Cash Flow	87.41	53.98	200.71	74.32	44.72
Foreign Exchange Rate Adjustments	0.61	-0.03	1.06	0.13	-0.35
Miscellaneous Cash Flow Adjustments	-	-	0	-0	0
Net Cash Flow	-1.19	-45.85	84.25	9.45	11.04
Cash Interest Paid	0.98	0.12	0.12	0.11	2.36
Cash Income Tax Paid	-8.43	-8.47	-7.86	-4.63	-3.17
Levered Free Cash Flow	-63.32	25.55	-86.61	-43.28	-12.14
Unlevered Free Cash Flow	-62.8	26.05	-86.43	-43.21	-12.11
Change in Net Working Capital	16.62	-29.67	21.47	-4.55	-7.45

Source: S&P Global Market Intelligence. Standard template. Financial Sources.